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Primarily, the role of the aromatase inhibitors has been investigated in postmenopausal women with breast cancer, although it is also
now being assessed in premenopausal patients following ovarian ablation/suppression. Aromatase inhibitors markedly suppress
endogenous oestrogens without directly interacting with oestrogen receptors, and thus have a different mechanism of action to the
antioestrogen, tamoxifen. The inhibitors may be divided into subgroups according to their structure (steroidal and nonsteroidal), and
there appears to be a lack of cross-resistance between the classes of aromatase inhibitors enabling them to be used sequentially and
potentially to prolong endocrine hormone therapy. In addition, with increased efficacy and favourable safety and tolerability profiles,
the aromatase inhibitors are starting to challenge tamoxifen as first choice endocrine treatment in a number of settings. Potential
differences in side-effect profiles may appear between the steroidal and nonsteroidal aromatase inhibitors when used in long-term
settings. Thus, it has been suggested that the steroidal agents have favourable end organ effects; for example, the steroidal inhibitor,
exemestane, has minimal negative effects on bone and lipid metabolism in animal and clinical studies. This paper provides an overview
of the current and future roles of aromatase inhibitors for breast cancer treatment.
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With many breast cancers requiring oestrogen for growth,
hormone therapy has focused on suppressing the synthesis and
action of these hormones. The gold standard for hormone therapy
in premenopausal women has been ovarian ablation, with anti-
oestrogens (such as tamoxifen) being primarily used in post-
menopausal patients. However, in postmenopausal women, an
alternative approach is to target the aromatase enzyme, which is
responsible for the conversion of androgens to oestrogens
and is the key step in oestrogen biosynthesis. Recent clinical
trial results with aromatase inhibitors suggest this approach has
an important role in treatment of ER and/or PgR positive
breast cancers.
RATIONALE FOR AROMATASE INHIBITORS IN
BREAST CANCER
Oestrogen deprivation has long been an effective treatment for
breast cancer (Beatson, 1896), and the introduction of the anti-
oestrogen, tamoxifen, in the 1970s produced marked improvements
in breast cancer survival (EBCTCG, 1998). Tamoxifen blocks the
oestrogen receptor, whose signalling represents a critical growth
and survival pathway in breast tumours. However, tamoxifen also
has some partial oestrogen agonist effects, which may be
detrimental, and may be associated with increased risk of uterine
cancer and thromboembolism. Agonist activity may also be
involved in the development of tamoxifen resistance (Smith and
Dowsett, 2003).
An alternative approach to blocking the oestrogen receptor is to
reduce levels of its ligand, oestradiol, by targeting aromatase. This
enzyme converts androstenedione and testosterone to oestrone
and oestradiol (Gruber et al, 2002). It is a member of the cyto-
chrome P450 class and is highly expressed in the placenta and in
the granulosa cells of ovarian follicles. However, it is also present
in peripheral tissues, including adipose tissue, liver, muscle,
brain and breast cancer tissue (Miller, 1991; Simpson and
Davis, 2001).
Unlike tamoxifen, aromatase inhibitors do not directly interact
with the oestrogen receptor but indirectly affect signalling in
postmenopausal women by blocking the conversion of adrenal
androgens to oestrogen in peripheral (ie non-ovarian) tissues,
including the breast itself (Figure 1; Miller, 1991). Enhanced
aromatase activity has been observed in adipose tissue adjacent
to breast cancers (O’Neill et al, 1988), and may promote growth of
malignant cells (O’Neill et al, 1988). Aromatase inhibitors inhibit
in situ oestrogen synthesis in both tumour and non-malignant
breast tissue (Miller and Dixon, 2001), and have demonstrated
efficacy in suppressing peripheral oestrogen synthesis in post-
menopausal women (Smith and Dowsett, 2003).
Aromatase inhibitors may be divided into two subtypes, steroidal
and nonsteroidal. Steroidal inhibitors (eg exemestane) are analogues
of androstenedione and bind irreversibly to the substrate binding
site on the aromatase molecule, and are also known as enzyme
inactivators. Nonsteroidal inhibitors (eg anastrozole and letrozole)
bind reversibly to the haem group of the enzyme. The clinical
significance of this difference in mechanism of action is uncertain at
present, although it may enable the different types of agent to be
used sequentially in order to prolong clinical response (Lønning
et al, 2000; Bertelli et al, 2002). Later in the supplement, Dr Bertelli
discusses sequencing of therapy further.
Several trials have shown that aromatase inhibitors are effective
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(Nabholtz et al, 2000; Milla-Santos et al, 2000; Dirix et al, 2001;
Mouridsen et al, 2001). In the adjuvant and neoadjuvant settings:
  The Arimidex, Tamoxifen Alone or in Combination (ATAC)
study (ATAC, 2002; Buzdar, 2004) has shown the aromatase
inhibitor, anastrozole, to be more effective than tamoxifen in
terms of disease-free survival (DFS) with several important
tolerability benefits.
  The Intergroup Exemestane Study (IES) showed that switching
to exemestane after only 2–3 years of tamoxifen therapy
significantly improved DFS vs the standard 5 years of tamoxifen
therapy (Coombes et al, 2004).
  Results from the MA-17 trial indicated that following the
completion of standard adjuvant tamoxifen therapy, letrozole
treatment improved DFS compared with placebo (Goss et al,
2003).
  In the neoadjuvant setting, the P024 trial demonstrated that
women with oestrogen receptor-positive primary breast cancer
who received letrozole were more likely to receive breast
conserving surgery compared with those treated with tamoxifen
(Ellis et al, 2001).
CURRENT GUIDELINES AND THE AROMATASE
INHIBITORS
Both the National Comprehensive Cancer Network (2005) and The
Cancer Care Ontario Practice Guidelines Initiative (Breast Cancer
Disease Site Group, 2002) have added aromatase inhibitors to their
guidelines alongside tamoxifen as first-line therapy in postmeno-
pausal oestrogen receptor-positive women with advanced breast
cancer. The European Society of Mastology has also added
aromatase inhibitors as first-line therapy in their advanced breast
cancer guidelines (Blamey, 2002).
Following the publication of the first results from the ATAC
study (ATAC, 2002), the American Society of Clinical Oncology
(ASCO) reviewed their guidelines on adjuvant treatment of breast
cancer (Winer et al, 2002, 2003). Their recommendations were
that a 5-year course of tamoxifen should remain as standard
therapy with adjuvant therapy with an aromatase inhibitor only
in postmenopausal women with a relative or absolute contra-
indication to tamoxifen.
CURRENT PRACTICE
In advanced disease, in the first-line setting, anastrozole, letrozole
and exemestane have proved to be more clinically efficient than
tamoxifen in prospective randomised trials and demonstrate a
more favourable side-effect profile (Bonneterre et al, 2000;
Nabholtz et al, 2000; Paridaens et al, 2000, 2003; Mouridsen
et al, 2001; Howell et al, 2003). In previous studies, all three have
also demonstrated superiority over megestrol acetate in the
second-line setting after tamoxifen failure (Buzdar et al, 1996,
1997; Dombernowsky et al, 1998; Goss et al, 1999; Kaufmann et al,
2000). Exemestane and letrozole have been shown to be active and
well tolerated after tamoxifen and megestrol acetate failure in the
third-line setting (Ingle et al, 1997; Jones et al, 1999). Furthermore,
an apparent lack of cross-resistance between the aromatase
inhibitors offers the possibility of sequential use in advanced
disease (see Dr Bertelli’s article later in this supplement).
In the neoadjuvant setting, letrozole has proved to be superior
to tamoxifen both in terms of tumour response and breast
conservation rate (Eiermann et al, 2001). Interestingly, a biological
evaluation of the study showed that tumours which overexpressed
HER2 receptors were more likely to respond to the aromatase
inhibitor than to tamoxifen (Ellis et al, 2001). Both anastrozole and
exemestane have also been shown to be more effective than
tamoxifen in the preoperative setting (Dixon et al, 1999a,b; Geisler
et al, 1999; Miller and Dixon, 2002).
In the adjuvant setting, while tamoxifen is the current standard
of care, four large randomised controlled studies have favourably
evaluated aromatase inhibitors against tamoxifen either ‘head to
head’ or in sequence with adjuvant tamoxifen (ATAC, 2002; Goss
et al, 2003; Buzdar, 2004; Coombes et al, 2004; Jakesz et al, 2004).
Interestingly, an analysis of the ATAC data shows that ER þve, PR
 ve patients may particularly benefit from an aromatase inhibitor
(ATAC, 2002; Buzdar, 2004).
SAFETY ISSUES
Data from postmenopausal women with advanced disease suggest
that steroidal and non-steroidal aromatase inhibitors have similar
tolerability profiles. In the ATAC study, patients receiving
anastrozole had fewer vascular and uterine adverse events than
those receiving tamoxifen (ATAC, 2002; Buzdar, 2004). Exeme-
stane was associated with less severe flushing, sweating, nausea
and oedema than tamoxifen (Paridaens et al, 2000; 2003). The
most commonly reported adverse events in women treated with
aromatase inhibitors were hot flushes, nausea, vomiting, headache
and fatigue.
Emerging data suggest that there may be differences between the
two types of aromatase inhibitor in their effects on end organs. The
steroidal agent exemestane may have positive or neutral effects on
lipid metabolism, as opposed to nonsteroidal agents which have
shown unfavourable or neutral effects, and may have less impact
Fat
muscle
adrenal gland
Exemestane
Exemestane
Androgen
Aromatase
Aromatase
Oestrogen
Oestrogen
Tamoxifen
Tamoxifen
Oestrogen
receptor
Oestrogen
receptor
Oestrogen
receptor
Tumour does
not grow
Tumour does
not grow
Tumour grows
Figure 1 Mechanisms of action of tamoxifen and exemestane.
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Studies with exemestane have shown mixed effects on bone;
exemestane has been seen to reverse the increased bone turnover
induced by ovariectomy in an animal model (Goss et al, 2001),
and in a comparison with letrozole, exemestane reduced bone
resorption markers (Goss et al, 2002). However, other studies have
also shown increased levels of bone turnover markers with
exemestane (Martinetti et al, 2003; Geisler et al, 2004). In the
adjuvant setting, increased osteoporosis has been demonstrated
in trials with all the third-generation aromatase inhibitors
(ATAC, IES, ARNO, MA17). Any differences between the
aromatase inhibitors will become evident with long-term use (eg
in adjuvant or prevention settings). Clinical trials are currently
under way to investigate these effects. The consequences of the
aromatase inhibitors on bone and lipids are explored further later
in the supplement.
FUTURE ROLE FOR AROMATASE INHIBITORS
Advanced disease
Anastrozole and letrozole are already licensed for first-line therapy
in advanced disease. Evidence suggests that in future exemestane
may also be approved for first-line use. Results from a phase II,
randomised, EORTC study comparing exemestane with tamoxifen
treatment in patients who had previously received no hormonal
therapy for metastatic disease revealed a better overall response
rate for exemestane than tamoxifen (41 vs 17%) (Paridaens et al,
2003). There was a lower incidence of severe flushing, sweating,
nausea and oedema in women who received exemestane than
tamoxifen. This study was extended into a phase III trial
comparing time-to-disease progression of the two agents, and
results for 382 patients were presented at the 2004 ASCO meeting.
Median progression-free survival was found to be significantly
longer with exemestane than tamoxifen (10.9 vs 6.7 months,
P¼0.04) and safety/tolerability assessments were also favourable
for the aromatase inhibitor (Paridaens et al, 2004).
Neoadjuvant therapy
Currently, letrozole is the only aromatase inhibitor licensed for use
as neoadjuvant therapy, based on the results of the P024 trial (Ellis
et al, 2001), where more women with oestrogen receptor-positive
(ERþve) primary breast cancer who received letrozole went on
to receive breast conserving surgery (60% responded and 48%
underwent successful breast-conserving surgery) compared with
tamoxifen (41% responded and 36% underwent breast conserva-
tion). Several other studies have suggested that aromatase
inhibitors may be more effective than tamoxifen in reducing
tumour size prior to surgery (Dixon et al, 1999a,b; Geisler et al,
1999; Miller and Dixon, 2002).
Adjuvant therapy
Tamoxifen is the most widely used endocrine agent for adjuvant
therapy, but it has drawbacks, in particular an increased risk
of thromboembolic events and endometrial changes, including
endometrial cancer (EBCTCG, 1998; Baum, 1999). Adjuvant trials
of all third generation aromatase inhibitors show superior efficacy
and equivalent or better tolerability. However, there are several
difficulties in assessing the role of adjuvant endocrine therapy.
Endocrine therapy is often administered in consort with
chemotherapy making it difficult to separate the endocrine effects
of the two types of treatment. Further head-to-head and
sequencing trials are currently running that should add to our
knowledge regarding use of the aromatase inhibitors in these
settings. As these trials report, it is hoped that a consensus will
emerge regarding whether aromatase inhibitors may replace
tamoxifen in the adjuvant setting or whether sequencing with
tamoxifen is more appropriate. Trials include:
TEAM: comparing adjuvant exemestane vs adjuvant tamoxifen
for 5 years in 4400 postmenopausal women with early breast
cancer. This is a phase III randomised trial.
BIGFEMTA: comparing 5 years of tamoxifen, 5 years of
letrozole, or sequenced therapy of 2–3 years each starting with
either tamoxifen or letrozole. The trial recruited a total of 8028
patients between 1998 and 2003. Primary Core Analysis results
presented at St Gallen 2005 show that letrozole significantly
increased DFS vs tamoxifen (P¼0.003) at a median follow-up of
35.5 months (Thu ¨rlimann, 2005).
ARNO: comparing 3 years’ treatment of anastrozole with 3 years
of tamoxifen, following 2 years’ treatment with tamoxifen. The trial
began in 1996, with initial data recently being reported in
combination with results from the ABCSG Trial (total n¼3123;
Jakesz et al, 2004). After a median follow-up of 26 months, the
hazard ratio for recurrence-free survival was 0.59 for anastrozole
vs tamoxifen (95% CI¼0.42–0.82; Po0.0018), and 0.61 for distant
recurrence-free survival (95% CI 0.42–0.87; P¼0.0067).
ICCG: comparing 2 years’ treatment of exemestane with 2 years
of tamoxifen, following 3 years’ treatment with tamoxifen.
Unresolved issues
Evidence from the ATAC trial suggests that combining tamoxifen
with anastrozole does not give additional benefit with results
equivalent to tamoxifen alone and worse than anastrozole alone.
The likely explanation for this is that in the low oestrogen
environment created by an aromatase inhibitor, tamoxifen is more
likely to display some agonist activity. Further, there is evidence in
the advanced setting that use of a steroidal aromatase inhibitor
after a nonsteroidal agent or vice versa can prolong clinical benefit
(Lønning et al, 2000; Bertelli et al, 2002). Therefore, more work is
needed to determine the optimal sequence of tamoxifen, steroidal
and nonsteroidal aromatase inhibitors.
Disease prevention
Significant reduction in the emergence of contralateral breast
cancer in all current adjuvant studies of third generation
aromatase inhibitors raises the question of whether they might
have a role in disease prevention, particularly bearing in mind
their favourable safety/tolerability profile, an especially important
consideration in this setting. Oestrogen has been implicated in the
development of breast cancer, and oestrogen metabolites may also
be directly carcinogenic; therefore, reduction in oestrogen levels in
high-risk women with high levels of oestrogen may be beneficial.
Among ongoing prevention trials are:
IBIS II: aims to determine the effectiveness of anastrozole
vs placebo in preventing breast cancer in healthy postmenopausal
women at risk, and comparison between tamoxifen and anastro-
zole in postmenopausal women with ductal carcinoma in situ in
10000 women.
ApreS: compares exemestane with placebo in prevention of
breast cancer in 666 women with the BRACA 1/2 mutation
(Bevilacqua et al, 2001).
Premenopausal women
Another possible role for aromatase inhibitors may be following
ovarian ablation/suppression in premenopausal women. Three
important, linked trials are investigating this:
SOFT: examining tamoxifen alone vs tamoxifen plus ovarian
function suppression vs exemestane plus ovarian function
suppression in 3000 patients.
TEXT: investigating the use of tamoxifen plus a gonado-
tropin-releasing hormone (GnRH) analogue with or without
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without chemotherapy in 1845 patients.
PERCHE: randomising patients from the TEXT trial into
PERCHE if the investigator and/or patient are uncertain about
the role of chemotherapy added to the complete oestrogen
blockade – the choice of whether or not to use chemotherapy
can be determined by randomisation in the PERCHE trial. Patients
can be enrolled in both trials – first PERCHE (to determine
whether or not chemotherapy is used) and then TEXT (to
determine choice of tamoxifen or exemestane). PERCHE aims to
enroll 1750 patients.
Combination with cyclooxygenase 2 (COX2) inhibitors
Following observations of cyclooxygenase 2 (COX2) involvement
in breast carcinogenesis, the therapeutic potential of combining
aromatase inhibitors with COX2 inhibitors is currently being
investigated. Studies have suggested that this might bring
improved response (Pesenti et al, 2001; Canney, 2003; Dirix et al,
2003). Early results of a feasibility study of exemestane plus the
specific COX2 inhibitor celecoxib in postmenopausal women with
histologically proven advanced or metastatic breast cancer showed
31% with a partial response and 42% having stable disease
following treatment with both agents (Canney, 2003). Now the
following clinical trials are underway:
  NCIC CTG MA 27 is a randomised 2 2 trial comparing
exemestane and anastrozole with or without celecoxib in 6800
women.
  The International Cooperative Breast Cancer Group/Breast
International Group (ICCG/BIG) trial is a phase III study
looking at sequential exemestane and tamoxifen with celecoxib
vs placebo.
Professor Bundred gives further consideration to this potential
combination later in this supplement.
CONCLUSIONS
Aromatase inhibitors are rapidly proving to be a valuable addition
to breast cancer therapy in postmenopausal women with oestrogen
receptor positive tumours. As results of ongoing clinical trials
become available, it is likely that these agents will be used earlier in
the course of the disease and in the prevention setting, and may be
used sequentially to prolong hormonal therapy and delay the need
for chemotherapy, and possibly become part of a combination
approach with other agents such as the COX2 inhibitors.
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